ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.027,59
-0,38%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,1348
-0,01%
Bitcoin
65.989,68
-0,41%
Brent Oil
82,855
0,24%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Notícias

ARGX argenx SE

376,96
20,95 (5,88%)
15 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
argenx SE ARGX NASDAQ Recibo de Depósito
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
20,95 5,88% 376,96 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
359,41 359,41 380,75 376,96 356,01
mais cotações »

Notícias Recentes

Data Hora Fonte Título
09/05/202402:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
07/05/202418:30GLOBEargenx announces results of Annual General Meeting of..
07/05/202402:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/05/202402:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/04/202402:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202403:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/03/202417:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202403:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/03/202418:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/02/202403:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202403:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202403:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202403:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202403:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202403:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202403:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202314:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202303:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202313:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202309:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202303:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202309:40GLOBEargenx Announces European Commission Approval of..
01/11/202303:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202303:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202302:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/09/202302:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/09/202302:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/08/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
27/07/202302:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/07/202317:30GLOBEargenx announces closing of global offering
20/07/202302:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/07/202318:58GLOBEargenx announces full exercise of underwriters’ option to..
18/07/202322:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/07/202317:58DJNArgenx Launches $750 Million Global Offering
17/07/202317:01GLOBEargenx announces launch of proposed global offering
17/07/202312:59DJNArgenx Up Over 30%, on Track for Record High Close -- Data..
17/07/202312:04DJNArgenx Shares Hit 52-Week High After Positive Vyvgart..
17/07/202308:10DJNArgenx, Zai Lab Shares Rise After Positive Trial Results for..
17/07/202302:03GLOBEZai Lab and argenx Report Positive Topline Data from ADHERE..
17/07/202302:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/06/202310:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
30/06/202310:22GLOBEZai Lab and argenx Announce Approval of VYVGART®..
20/06/202320:09DJNArgenx Says FDA Approves Vyvgart Hytrulo Injection to Treat..
20/06/202319:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/06/202302:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/05/202302:00GLOBEargenx to Present at Upcoming Investor Conferences

Seu Histórico Recente

NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados